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ABSTRACT The diarrheal pathogen Clostridium difﬁcile consists of at least six distinct
evolutionary lineages. The RT017 lineage is anomalous, as strains only express toxin
B, compared to strains from other lineages that produce toxins A and B and, occa-
sionally, binary toxin. Historically, RT017 initially was reported in Asia but now has
been reported worldwide. We used whole-genome sequencing and phylogenetic
analysis to investigate the patterns of global spread and population structure of 277
RT017 isolates from animal and human origins from six continents, isolated between
1990 and 2013. We reveal two distinct evenly split sublineages (SL1 and SL2) of C.
difﬁcile RT017 that contain multiple independent clonal expansions. All 24 animal
isolates were contained within SL1 along with human isolates, suggesting potential
transmission between animals and humans. Genetic analyses revealed an overrepre-
sentation of antibiotic resistance genes. Phylogeographic analyses show a North
American origin for RT017, as has been found for the recently emerged epidemic
RT027 lineage. Despite having only one toxin, RT017 strains have evolved in parallel
from at least two independent sources and can readily transmit between continents.
KEYWORDS Clostridium difﬁcile, sequencing, SNPs, ribotype 017, evolution,
phylogenetics, antibiotic resistance, phylogeny
Clostridium difﬁcile is a spore-forming obligate anaerobe that continues to be theleading cause of health care-associated infections in the developed world (1, 2).
There are six main lineages that broadly split into PCR ribotypes (RTs) associated with
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RT027, RT023, RT017, RT078, a grouping of diverse RTs, and the recently identiﬁed novel
lineage containing RT131 (3). The global emergence of the RT027 strain was responsible
for multiple outbreaks and increased disease severity in Canada and the United States
in 2001 (4). This strain has since spread to South America (5–7), China (8), Japan (9),
Hong Kong (10), South Korea (11, 12), Taiwan (13), Singapore (14), Australia (15, 16),
Saudi Arabia (17), Israel (18), New Zealand (19), and throughout Europe (5, 20–28).
Although RT027 remains the dominant clone in the United States, Europe has seen a
decline in RT027 with a simultaneous increase in other virulent RTs, such as RT017 and
RT078 (29).
Using whole-genome sequencing (WGS) and phylogenetic analysis, He et al. (4)
identiﬁed the presence of two genetically distinct sublineages of RT027 through
single-nucleotide polymorphism (SNP) analysis; both had emerged in North America
within a relatively short period after acquiring the same ﬂuoroquinolone resistance-
conferring mutation containing an alteration in gyrA and a highly related conjugative
transposon (4). The two epidemic sublineages showed distinct patterns of global
spread, with one lineage spreading more widely and causing health care-associated
outbreaks globally (4).
Traditionally, virulent C. difﬁcile strains are characterized and identiﬁed in diagnostic
laboratories by the presence of two potent toxins, TcdA and TcdB (30). These genes are
located on a 19.6-kb pathogenicity locus (PaLoc). There is genetic variation in this
region which can be exploited and which has revealed 30 different toxinotypes,
including six A B toxinotypes. The most common and clinically relevant is toxinotype
VIII, and these isolates belong to RT017 (31). It is well known that the tcdA gene of this
type contains a 1.8-kb deletion at the 3= end and a nonsense mutation at tcdA amino
acid 47 that introduces a stop codon leading to a truncated tcdA gene (31). RT017
strains also lack the binary toxin (CDT) found in, for example, pathogenic RT027 strains
that produce all three toxins. Despite lacking two toxins, clinically signiﬁcant C. difﬁcile
infection (CDI) has been reported worldwide for the RT017 lineage (32–41).
Historically, these strains were initially identiﬁed in CDI outbreaks in Asia and are
thought to have spread to Europe and other continents. RT017 strains have been
reported in Canada (35, 42), China (34, 43), South Korea (33, 44, 45), Argentina (46),
Australia (47, 48), Israel (49), Japan (50), South Africa (51), and throughout Europe (36,
39, 41, 52, 53). These strains have also been isolated from nonhuman sources, including
equines, bovines (54), and rabbits (55). We recently performed WGS on 35 human and
two hospital environmental isolates of RT017 circulating in London, United Kingdom,
and identiﬁed three SNP variants (39). One variant was found to be clonal and had
persisted in a London hospital ward for at least 5 years (39).
Here, WGS and phylogenetic analysis were used to deﬁne the population structure
of a collection of 277 RT017 isolates from six continents of human and nonhuman
origins with isolation dates between 1990 and 2013. Analyses reveal that RT017 strains
have evolved in parallel from at least two independent sources and can readily transmit
between continents. Genotypic and phenotypic antimicrobial susceptibilities were also
compared.
RESULTS
WGS was performed on a global collection of 277 C. difﬁcile RT017 isolates (Table 1).
Collectively, these were isolated from human (n 251), bovine (n 9), canine (n 11),
equine (n  4), and hospital ward environments (n  2) between 1990 and 2013 (see
Information S1 in the supplemental material). All isolates belonged to multilocus
sequence type 37. After sequence quality control and mapping to the M68 RT017
reference genome (GenBank accession number FN668375), we identiﬁed 1,288 high-
quality biallelic SNPs, with 311 present in greater than 1% of samples and greater
than 1 bp from an insertion or deletion. Of these non-rare SNPs, 65.6% (n  204)
were nonsynonymous, 17.7% (n  55) were synonymous, and 16.7% (n  52) were
present in noncoding regions of the genome (nonsynonymous SNPs are shown in
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Information S2). Twelve SNPs affected stop codons, 11 nonsynonymous and 1 synon-
ymous (Table 1).
SNP data revealed 109 haplotypes containing between 0 and 52 SNPs (with respect
to the M68 reference), with 76.5% (212/277) of isolates having between 10 and 35 SNPs
(Table 2).
We generated a maximum-likelihood phylogenetic tree based on the 1,288 SNPs
that demonstrated the presence of two genetically diverse sublineages, SL1 and SL2
(Fig. 1 and 2). Of the 1,288 SNPs, 76% (977/1,288) had a minor allele frequency (MAF)
of1% and/or were within 1 bp of an insertion or deletion. To control for false-positive
identiﬁcation of SNPs (these SNPs may mask the true phylogeny of RT017), phyloge-
netic trees with and without these SNPs were generated. The inclusion of 977 SNPs had
a minor effect on the overall phylogenetic tree. Four SNPs were found to differentiate
the two sublineages, one present in a noncoding region and three nonsynonymous
SNPs (Table 3). SL2 is the most distantly related to the reference M68 strain of the two
sublineages, and both sublineages are geographically and temporally widespread. All
isolates from the previously reported study on London isolates fell into SL2 (39).
The RT017 strains are documented to have a higher level of antibiotic resistance
than other C. difﬁcile RTs (37, 56). Fluoroquinolone resistance in C. difﬁcile has been
associated with mutations in codon 82 of the gyrA gene and codon 426 of the gyrB
gene. The common SNP found in the gyrA gene is T82I, and those in the gyrB gene are
A426V and A426A (57). Remarkably, we found 64.6% (179/277) to have the amino acid
substitution found in the gyrA gene (T82I). A substitution in the gyrB gene (V426N) was
present in 4.7% of strains (13/277), and an additional 10.1% (28/277), including M68,
harbored a valine at position 426 of the predicted gyrB product (Table 2; Information
S1). The T82I substitution was globally distributed in both sublineages. Additionally,
substitutions in the 81-bp rifampin resistance-determining region of the rpoB gene,
R505K, H502N, and S485F, were found in 32.5% (90/277), 33.2% (92/277), and 1.1%
(3/277) of isolates, respectively (Table 2; Information S1).
To investigate horizontal gene transfer, a key mechanism driving C. difﬁcile evolu-
tion, we performed programmatic and visual inspection of the comparisons, which
revealed 56 regions of DNA between 4 and 61.5 kb that were absent from the M68
strain but present in other strains. These had 34 different insertion sites (Table 2 and
Fig. 3; Information S1 and S4). Additionally, we found regions of DNA of between 8
and 29 kb present in the M68 strain at six sites but absent from multiple samples
(Table 2; Information S1 and S3). These insertions and deletions were associated with
erythromycin, teicoplanin, tetracycline, chloramphenicol, and beta-lactam resistance
genes, and their products potentially associated with virulence, such as a two-
component response regulator, a SAM protein, an AntA/AntB antirepressor, a cell
surface protein, and a sporulation-speciﬁc glycosylase (Information S3 and S4). The
TABLE 1 Stop codon-associated SNPs
Position
in M68
genome
Codona
Nonsynonymous/
synonymous/
noncoding Gene Predicted function and/or potential impact
No. of
isolates
with SNPM68 reference Alternative
132573 TGG TGA Nonsynonymous M68_00168 Amino acid aminotransferase 16
557896 TTC* TAA* Nonsynonymous feoB3 Ferrous iron transport protein B 3
1204039 GGA TGA Nonsynonymous M68_01144 Hydrolase 36
1359584 GGA TGA Nonsynonymous M68_01270 Extracellular solute-binding protein 3
1907433 TAA GAA Nonsynonymous msrAB Peptide methionine sulfoxide reductase 256
1916756 AAT* GAT* Synonymous M68_01782 Unknown 3
3304067 TCA* GCA* Nonsynonymous Sigma-54 Controls expression of nitrogen-related genes 29
3399853 TTG* TAA* Nonsynonymous M68_03193 Ca2/Na antiporter 13
3402470 CAA TAA Nonsynonymous plfB Formate acetyltransferase 3
3704987 CCA* TGA* Nonsynonymous sleB Spore-cortex-lytic protein 8
3784055 TTC* TAA* Nonsynonymous M68_03513 Penicillin-binding protein 3
4157880 TTG* TAA* Nonsynonymous M68_03851 PTS system, IIc component 6
a*, Located on the reverse strand.
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deletions and insertions were well distributed geographically and temporally, and a
49-kb insertion found only in a clonal cluster of 23/37 London isolates in our previous
study (39) was also found to insert at a different site in single isolates from Canada, the
United States, and the United Kingdom, with isolation dates of 2006, 2006, and 2011,
respectively (Fig. 3). Only one SNP was found in the toxin pathogenicity locus region,
which was synonymous and present in the nonfunctioning tcdA gene fragment from
ﬁve South Korean isolates in SL2 isolated between 2004 and 2008. Visual inspection of
the comparisons revealed both tcdA and tcdB genes to be highly conserved; no
sequence variations were found.
MICs were determined for eight C. difﬁcile isolates (including M68 as a control)
against the antibiotics chloramphenicol, rifampin, tetracycline, erythromycin, nalidixic
acid, gentamicin, teicoplanin, and ampicillin. Their MICs are shown in Table 4. All
isolates were resistant to nalidixic acid, gentamicin, and ampicillin, were either resistant
or intermediately resistant to tetracycline, and were sensitive to teicoplanin. Out of
eight isolates, two were resistant to chloramphenicol, four were resistant to rifampin,
and seven were resistant to erythromycin.
DISCUSSION
The RT017 lineage, with its unique toxin proﬁle and unusual global prevalence, has
been overshadowed by the global outbreak of the RT027 lineage. Reminiscent of the
RT027 lineage, two distinct sublineages of C. difﬁcile RT017 that contain multiple
FIG 1 Maximum-likelihood phylogenetic analysis of 277 global RT017 isolates based on core genome SNPs against
the M68 reference. We used non-rare (1% MAF) SNPs that were not in close proximity to insertions or deletions
to determine the phylogenic tree. The SL1 and SL2 sublineages were differentiated by four SNPs (Table 3), with the
reference strain M68 falling into SL2. The colored nodes indicate the geographical source of isolates.
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independent clonal expansions were revealed in this study. This division demonstrates
that toxin variant strains emerged on at least one occasion, suggesting that a full toxin
repertoire is not essential for efﬁcient human-to-human transmission.
Based on our gyrA and gyrB SNP data, we predict up to 76.2% (211/277) of isolates
are resistant to the ﬂuoroquinolone class of antibiotics. Interestingly, the T82I SNP
found in gyrA is the same mutation reported in the global outbreak of RT027 (4). Based
on our MIC data, all eight isolates were resistant to nalidixic acid, indicating resistance
to the ﬂuoroquinolone class of antimicrobials.
Based on our rifampin SNP data, we predict 34.7% (96/277) of isolates in this study
are resistant to the rifampin class of antibiotics. Interestingly, 82% (152/185) of these
substitutions were found in SL1. R505K and H502N have previously been associated
with rifampin resistance in C. difﬁcile (60); however, based on our MIC data, only two
(2/8) isolates were sensitive to rifampin, with one of the isolates containing the R505K
and H502N SNP, indicating that these alone do not always lead to phenotypic resis-
tance. Interestingly, S485F was found in three historical isolates from Wrexham, United
Kingdom. This resistance-conferring SNP previously has been reported only in Myco-
TABLE 3 Lineage-deﬁning SNPs
Position
Amino
acid
Base
Nonsynonymous/
synonymous/
noncoding
Gene
product
Predicted function
and/or potential
impactReference Alternative
650374 19 A G Nonsynonymous MerR Altered response to
environmental
stimuli
900866 C T Noncoding
2914248 257 A G Nonsynonymous DacF -Lactam resistance
3604289 329 C A Nonsynonymous Hypothetical
protein
Unknown
FIG 2 Maximum-likelihood phylogenetic analysis of 277 global RT017 isolates based on core genome
SNPs against the M68 reference. The phylogeny is separated into individual panels corresponding to
each continent. Data from 5 out of 7 continental designations (Africa, Europe, Asia, Oceania, and North
America) include SL1 and SL2 isolates, indicating that both sublineages are global in nature.
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bacterium tuberculosis and not in C. difﬁcile (61). All three isolates were phenotypically
resistant to rifampin; however, all three isolates also contained the R505K SNP, con-
ﬁrming this SNP’s contribution to resistance was not possible.
The multiple haplotypes revealed is similar to those found for the RT027 global
FIG 3 Bayesian evolutionary analysis of 277 global RT017 isolates based on core genome SNPs against the M68 reference. Using a geotemporal model, we can orient
the evolution of the RT017 isolates though time. The analysis indicates a split from SL1 (lower) into SL2 (upper) c1990, with the M68 reference in SL2. The introduction
of resistance-associated SNPs (such as in rpoC) fall within closely related groups in the phylogeny. The continents are colored as described for Fig. 1 and 2. The heat
map depicts the sublineage, presence/absence of insertions, and antimicrobial resistance-associated SNPs in relation to the isolates and continent.
TABLE 4 Antimicrobial susceptibility data and genotypic characteristics
Parameter
Value(s) for straind:
M68 S-017.72 WA 1514 S-017.92 S-017.27 S-017.74 I6 01-116
Location Ireland Walsall, UK Australia China Wrexham, UK Walsall, UK Indonesia South Korea
Yr isolated 2006 2011 2012 2009 1996 2011 2011 2001
Insertion A, B, C A D, E F, G
Deletion H H, I J H, J, K H, J
Resistant SNPs
rpoB (R505K) ✓ ✓ ✓ ✓ ✓
rpoB (H502N) ✓ ✓ ✓ ✓ ✓
rpoB (S485F) ✓
gyrA (T82I) ✓ ✓ ✓ ✓
gyrB (V426I) ✓
gyrB (V426D) ✓ ✓ ✓ ✓ ✓ ✓ ✓
Antimicrobial agent
Chloramphenicola 8 (S) 8 (S) 4 (S) 64 (R) 8 (S) 8 (S) 256 (R) 8 (S)
Rifampina 0.008 (I) 2 (I) 0.004 (S) 256 (R) 256 (R) 0.004 (S) 256 (R) 256 (R)
Tetracyclineb 32 (R) 32 (R) 0.25 (I) 32 (R) 32 (R) 0.25 (I) 32 (R) 32 (R)
Erythromycinb 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 2 (S) 256 (R) 256 (R)
Nalidixic acidb 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R)
Gentamicinc 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R)
Teicoplaninc 1 (S) 1 (S) 1 (S) 1 (S) 1 (S) 1 (S) 1 (S) 1 (S)
Ampicillinb 8 (R) 8 (R) 8 (R) 8 (R) 8 (R) 4 (R) 4 (R) 8 (R)
aRecommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (http://www.eucast.org/clinical_breakpoints/).
bRecommended by the CLSI (M11-A8 [58] and M100-S23 [59]).
cNo guidance from CLSI or EUCAST. Cutoffs are based on data according to CLSI guideline M100-S23 (interpretative values for Staphylococcus aureus).
dS, sensitive; I, intermediate resistance; R, resistant. Insertions: A, putative drug/sodium antiporter and radical SAM protein TetR-family transcriptional regulator; B,
transcriptional repressor DicA; C, streptogramin A acetyltransferase and multidrug resistance protein; D, putative beta-lactamase repressor; E, putative drug/sodium antiporter;
F, TetR family transcriptional regulator; G, chloramphenicol o-acetyltransferase (M68 has one copy of chloramphenicol); H, dimethyladenosine transferase (ermB); I, putative
teicoplanin resistance protein and putative beta-lactamase repressor; J, aminoglycoside 6-adenylyltransferase; K, putative conjugative transposon FtsK_SpoIIIE-related protein.
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study, where 100 distinct genotypes were found in 151 isolates. Despite SNPs and
insertions and deletions, there was no variation in susceptibility to ampicillin, teicopla-
nin, gentamicin, or nalidixic acid. However, there was some variation with chloram-
phenicol, rifampin, tetracycline, and erythromycin. Whether the insertions carrying
chloramphenicol o-acetyltransferase, the TetR-family transcriptional regulator, or the
ermB gene played a role in this variation is unknown.
Figure 4 depicts the phylogeny of the isolates by source. Interestingly, the 24 animal
strains, which were all isolated from a similar location (Ontario, Canada) over a relatively
short time period (2002 and 2005), are distributed among human isolates in SL1 only.
This suggests there is transmission between humans and animals.
The ready global distribution of RT017 suggests determinants independent of toxin
B are important in transmission. This could be related to the ready acquisition of
antibiotic resistance determinants, efﬁcient germination, and/or spore formation. This
study provides the basis to further investigate factors important for the epidemic
spread of C. difﬁcile.
The deletions and insertions were well distributed geographically and temporally,
suggesting either the rapid dissemination of strains or the multiple independent
acquisitions and loss of DNA regions (Fig. 2; Information S1). The insertion of different
clusters of genes at the same site suggests hot-spot regions for the uptake of DNA
(Information S4), and a 49-kb insertion found only in a clonal cluster of 23/37
London isolates in our previous study (39) was also found to insert at a different site
in single isolates from Canada, the United States, and the United Kingdom, with
isolation dates of 2006, 2006, and 2011, respectively (Fig. 3). This suggests these
isolates have independently acquired this insertion.
FIG 4 Maximum-likelihood phylogenetic analysis of the global RT017 isolates based on core genome
SNPs against the M68 reference depicting the 24 animal isolates by colored nodes. Note the three equine
isolates are positioned (and masked) by the bovine and canine cluster on the left. The two bovine isolates
on the right of the tree have an SNP distance of 17 from the bovine, canine, and equine cluster. All animal
isolates are from Ontario, Canada, and were isolated between 2002 and 2005.
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Similar to RT027, our analyses support a North American origin for RT017 with
multiple, global transmission events, with its earliest movement into Europe in 1986
(Fig. 4 and 5). The North American health system and practices appears to facilitate the
ready evolution and epidemic spread of C. difﬁcile for RT027 (4) and now, in this study,
for RT017. Our data show that it was Europe that introduced RT017 to Asia and
Australia, with subsequent spread from Asia to the Middle East, South America, and
South Africa. The analysis indicates over 40 movements back and forth over the span
of 30 years, consistent with population movements of a globalized society. Tradition-
ally, it has been considered that RT017 strains emerged from Asia due to the reported
high incidence of this RT that could not relate to or depend on toxin A-based assays for
diagnosis (40). However, our analysis does not support an “out-of-Asia” hypothesis and
supports a North American origin (Fig. 4 and 5).
This study investigated the genetic diversity of 277 C. difﬁcile RT017 isolates with
temporal, geographical, and source variation. Phylogeographic analysis of the SNPs
identiﬁed through WGS of the isolates suggests that there are two main sublineages of
RT017 that share an ancestry and are globally disseminated. Both sublineages contain
isolates from diverse geographical locations and isolation dates, with animal isolates
spread among human isolates in SL1. Together with the haplotype diversity and
geographically and temporally diverse presence of the transposable elements, these
data suggest widespread transcontinental spread and recombination with independent
acquisition and loss within different clusters.
MATERIALS AND METHODS
The 277 isolates described in this study are shown in Table 1 and included 37 isolates from a previous
study (ENA study accession number ERP009770) (39), with the remaining being new to this study (ENA
study accession number PRJEB11868). These were of human (n 251), environmental/hospital ward (n
2), equine (n  4), canine (n  11), and bovine (n  9) origin, with isolation dates between 1990 and
2013. These isolates were subjected to genomic DNA extraction as previously described by Stabler et al.
(62). WGS data for the isolates was obtained using either the HiSeq 2000 sequencing system or the MiSeq
sequencing system (Illumina, California), and libraries were created as previously described (63) or using
a Nextera XT kit (Illumina, California), respectively. The sequence data were processed and quality
controlled according to a standard pipeline as previously described (64). Brieﬂy, FASTQ-formatted
sequencing reads were quality controlled with a minimum quality Phred score of 30 (as a rolling average
over 4 bases) using trimmomatic (65). The resulting reads were mapped using the BWA-MEM (66)
software against the M68 C. difﬁcile reference strain, and the majority of posttrimmed reads (92% for
all samples passing quality control) were mapped to the reference. SNPs were called using SAMtools/
VCFtools (67).
Velvet (68) and Velvet Optimizer (http://bioinformatics.net.au/software.velvetoptimiser.shtml) were
used to de novo assemble the trimmed reads into contigs, producing 277 assemblies. Optimal k-mers fell
between 53 bp and 97 bp, and the mean value for median contig size of genome assembly (n50) was
FIG 5 Global transmission events inferred from Bayesian evolutionary analysis of RT017. From the geotemporal
analyses we can infer the ﬁrst movements into each continent, with the date and originating continent. The
analysis indicates a North American origin with an expansion into Europe in the mid-1980s, followed by a move
into Asia and on to Africa and South America through the 1990s and early 2000s. RT017 was not identiﬁed in
Oceania (Australia) until the late 2000s, via a jump from Europe.
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over 928,000 bp. The mean longest contig was 1,067,000 bp, with 71 samples producing contigs that
covered over half of the genome (greater than2.15 Mbp), and 16 samples assembled to contigs greater
than 4 Mbp (equivalent to greater than 90% of the genome). Pipeline, post-, genetic, phylogenetic,
phylogeographic, and cluster analyses were carried out using Perl, R, abacas, prokka, RaXML, Bayesian
evolutionary analysis sampling trees (BEAST), and mclust software (69–73). A minor allele frequency
(MAF) of less than 1% was used. To remove any SNPs that may be associated with recombination and
which would mask the true phylogeny, SNPs within 1 bp of an insertion or deletion site were excluded
from further analysis. We used BEAST (72) to produce an SNP phylogeny from the SNPs, as well as
geographical and temporal data combined in phylogeographic analysis and mclust software for maxi-
mum likelihood cluster analysis.
To determine the MICs of 7/277 isolates, dilutions for the antibiotics chloramphenicol, rifampin,
tetracycline, erythromycin, nalidixic acid, gentamicin, teicoplanin, and ampicillin were made as previously
described (74). Brieﬂy, 10 ml preequilibrated brain heart infusion broth, supplemented with yeast (Oxoid),
L-cysteine (Sigma), and C. difﬁcile supplement (Oxoid) (BHIS), were inoculated with three colonies of 48-h
culture on BHIS agar plates. Once the optical density (OD) reached 0.3 nm, 24-well plates containing the
antibiotic dilutions were inoculated with 1/100 of the BHIS broths and incubated. The ODs were
measured 24 h postinoculation, and MIC data were categorized as susceptible, intermediate, and
resistant by following the Clinical and Laboratory Standards Institute (CLSI) and the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) guidelines. The reference strain M68 was used as a
control, as were appropriate negative controls.
Accession number(s). Sequence data were deposited in the European Nucleotide Archive under
study accession number PRJEB11868.
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